atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$2.12 USD
+0.07 (3.41%)
Updated May 6, 2024 04:00 PM ET
After-Market: $2.12 0.00 (0.00%) 7:24 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATAI 2.12 +0.07(3.41%)
Will ATAI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ATAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATAI
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
ATAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
Elevance Health (ELV) & Verizon Partner to Bring Health Equity
Other News for ATAI
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Here's What You Missed in Cannabis, Psychedelics This Week
Psychedelic drug developers could benefit from NIH funding for chronic pain
Here's What You Missed in Cannabis, Psychedelics This Week
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression